LEO Pharma asserted new data exhibiting long-term improvements in psoriasis on nail iwth Kyntheum when compared to placebo or ustekinumab. Psoriasis on nail is usually tough to treat affecting approximately half of the estimated 125 million people living with psoriasis worldwide.
Psoriasis is a common, chronic, immune-mediated, inflammatory disease that primarily involves the skin impacting emotional, psychological and physical health. The heavy and far-reaching burden of the disease can be disabling and stigmatising with a substantial negative impact on those affected and their families. Due to the visible nature of the condition, psoriasis on the nail can be particularly upsetting for patients. In moderate to severe cases, psoriasis on the nail can be painful and restrict movement in the fingers and toes.
The efficacy of Kyntheum in psoriasis on the nail (as measured by NAPSI, the nail psoriasis severity index) was assessed based on the outcomes of two randomised Phase III clinical studies, AMAGINE-2 and -3. Results showed that in patients with psoriasis on the nail, Kyntheum decreased the NAPSI score in the most affected nail at week 52 and was associated with a lower NAPSI score than ustekinumab and placebo.
Kim Domela Kjoeller, Executive Vice President, Global Research & Development, LEO Pharma said “These, and other data presented at AAD, reinforce the safety and efficacy of Kyntheum and solidify its positioning as a leading biologic treatment option for people living with psoriasis.”
Kyntheum is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy. It is the first and only biologic treatment for psoriasis that targets the receptors through which the interleukin (IL)-17 cytokines – a family of proteins involved in immune responses – need to signal to cause the inflammation associated with psoriasis.